FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E mutation
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 11, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Braftovi (encorafenib) with Mektovi (binimetinib) for Metastatic Non-Small Cell Lung Cancer with a BRAF V600E Mutation
NEW YORK--(BUSINESS WIRE) October 12, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) + Mektovi® (binimetinib) for the treatment of adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 11, 2023 Category: Drugs & Pharmacology Source Type: news
ASTRO: Liquid Biopsy Can Stratify Risk in Oligometastatic NSCLC
WEDNESDAY, Oct. 11, 2023 -- Liquid biopsy, which identifies circulating tumor DNA (ctDNA), performed before radiotherapy (RT) can stratify risk for oligometastatic non-small cell lung cancer (NSCLC) patients, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 11, 2023 Category: Pharmaceuticals Source Type: news
Lunit to showcase AI research at ESMO 2023
AI developer Lunit will present nine studies featuring the company's AI pathology technology at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, being held October 20 to 24, 2023.The abstracts will cover a variety of areas and include the following:AI for prediction of multiple druggable mutations in non-small cell lung cancer from H&E stained imagesLunit Scope IO for distinguishing mismatch repair deficiency from mismatch repair proficiency colon cancers by analyzing features in whole slide imagesAI investigating the efficacy and safety of avelumab plus gemcitabine in leiomyosarcom...
Source: AuntMinnie.com Headlines - October 10, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
ctDNA Pre-Radiation Predicts Oligometastatic NSCLC Survival ctDNA Pre-Radiation Predicts Oligometastatic NSCLC Survival
Measuring ctDNA levels before radiotherapy predicted PFS and overall survival, and can help determine the patients most likely to benefit from consolidation radiotherapy vs systemic therapy.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 9, 2023 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Sotorasib's Confirmatory Data in NSCLC Unreliable, Says FDA Panel
(MedPage Today) -- An FDA advisory committee on Thursday said the confirmatory trial data for the KRAS inhibitor sotorasib (Lumakras) in previously treated non-small cell lung cancer (NSCLC) cannot be reliably interpreted in the CodeBreaK 200 study... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 6, 2023 Category: American Health Source Type: news
Can ctDNA Guide Radiation Use in Oligometastatic NSCLC?
(MedPage Today) -- SAN DIEGO -- A liquid biopsy may predict which patients with oligometastatic non-small cell lung cancer (NSCLC) are likely to benefit from consolidative targeted high-dose radiation, a researcher reported here.
In a retrospective... (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - October 5, 2023 Category: Radiology Source Type: news
Drugmaker Plans to Pull Lung Cancer Therapy From the Market
(MedPage Today) -- Mobocertinib (Exkivity) will be withdrawn from the U.S. market after a failed confirmatory trial in non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations, drugmaker Takeda announced.
In the phase... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 4, 2023 Category: American Health Source Type: news
FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLC
(MedPage Today) -- Ahead of a meeting of the Oncologic Drugs Advisory Committee on Thursday, FDA reviewers raised a host of concerns about the confirmatory trial data for sotorasib (Lumakras) in previously treated non-small cell lung cancer (NSCLC... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 4, 2023 Category: American Health Source Type: news
Social Disadvantage Tied to Worse Lung Cancer Outcomes
THURSDAY, Sept. 28, 2023 -- Social disadvantage is associated with a lower likelihood of achieving textbook oncological outcome and worse survival in patients with non-small cell lung cancer (NSCLC), according to a study published online Sept. 19 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 28, 2023 Category: Pharmaceuticals Source Type: news
Anti-TIGIT Plus Immunotherapy 'Promising' in NSCLC, Esophageal Cancer
(MedPage Today) -- Combination treatment with an investigational anti-TIGIT drug plus a PD-L1 inhibitor was well tolerated and demonstrated promising activity in patients with metastatic non-small cell lung cancer (NSCLC) and esophageal cancer... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 28, 2023 Category: Hematology Source Type: news
Combo Immunotherapy With Durvalumab Effective for NSCLC
MONDAY, Sept. 25, 2023 -- For patients with resectable non-small cell lung cancer (NSCLC), combination immunotherapy with the anti-programmed death-ligand 1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2023 Category: Pharmaceuticals Source Type: news
Merck and Eisai say two lung-cancer trials failed to meet their main goals
Merck and Japanese partner Eisai said Friday that two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet their primary goals in a disappointing outcome, but said they would continue to push ahead with their research. The companies said the LEAP-006 and…#merck #eisai #keytruda #lenvima #nsclc #gregorylubiniecki #rcc (Source: Reuters: Health)
Source: Reuters: Health - September 22, 2023 Category: Consumer Health News Source Type: news
NIVO/IPI Combo Demonstrates Long-Term Efficacy in NSCLC NIVO/IPI Combo Demonstrates Long-Term Efficacy in NSCLC
After 6 years, previous tumor response, tumor burden reduction, and baseline health-related quality of life all correlated with overall survival.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
' Aspirationally Resectable'? Neoadjuvant Tx Evolves in NSCLC'Aspirationally Resectable'? Neoadjuvant Tx Evolves in NSCLC
H. Jack West, MD, and Julia Rotow, MD, discuss clinical implications of thoracic oncology research presented at ASCO 2023.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
